Quanterix Stock Price, News & Analysis

Quanterix (NASDAQ: QTRX) has announced the commercial availability of its Simoa® p-Tau 217 Planar Kit for Alzheimer's Disease (AD) test development. This kit utilizes p-Tau 217 antibody technology licensed from Eli Lilly and Company and Quanterix's SP-X platform. The move expands access to this technology, allowing customers to develop p-Tau 217 blood tests and services for research use only (RUO).

This development follows Quanterix's March 2022 announcement of license and collaboration agreements with Lilly. The kit is now available immediately, supporting Quanterix's focus on building a global infrastructure for blood-based AD testing. The company aims to lead in Alzheimer's Disease testing for new research and therapies, ultimately advancing patient care and outcomes.

Quanterix (NASDAQ: QTRX), a leader in ultrasensitive biomarker detection, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. CEO Masoud Toloue and CFO Vandana Sriram will engage in a fireside chat on September 6, 2024, at 1:50 p.m. ET.

The presentation will be accessible virtually, with registration available online. Following the conference, the presentation will be viewable on Quanterix's website in the investor relations section. This event provides an opportunity for investors and stakeholders to gain insights into Quanterix's innovative Simoa® technology and its role in advancing scientific discovery through precise biomarker detection.

Quanterix (NASDAQ: QTRX) has appointed Jeffrey Elliott to its Board of Directors. Elliott brings 20 years of senior leadership experience in the medical diagnostics industry, including 8 years at Exact Sciences Corp. as CFO and COO. His expertise includes finance, strategy, and business development, with a track record of scaling operations and achieving high revenue growth. Elliott's appointment comes at a important time as Quanterix builds infrastructure for Alzheimer's Disease testing.

Elliott's background includes roles as a senior equity research analyst covering health care companies and a CFA® charterholder. He holds a B.S. in Business Administration from the University of Illinois and an MBA from the University of Chicago. Quanterix CEO Masoud Toloue and Board Chairman Martin Madaus expressed enthusiasm about Elliott's addition to the board, citing his valuable experience in scaling operations and financial expertise.

Quanterix (NASDAQ: QTRX) reported Q2 2024 financial results with revenue of $34.4 million, up 10.8% year-over-year. The company's research business showed strong performance, with Accelerator service revenue increasing 35%. However, Quanterix reported a net loss of $9.5 million, an increase of $3.4 million compared to the prior year period.

Key highlights include:

• GAAP gross margin of 58.3%, down from 61.7% in Q2 2023
• Net cash usage of $5.1 million
• Ended the quarter with $299.5 million in cash and equivalents
• Revised 2024 revenue guidance to $134-$138 million
• Presented data at AAIC demonstrating successful validation of a multi-marker approach for Alzheimer's disease detection
• Announced partnerships with Mt. Sinai, Banner Health, UCSF, and KingMed Diagnostics for Alzheimer's diagnostic testing

Quanterix (NASDAQ: QTRX), a company specializing in ultra-sensitive biomarker detection, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. CEO Masoud Toloue and CFO Vandana Sriram will engage in a fireside chat on August 13, 2024, at 3:00 p.m. ET. The presentation will be accessible virtually, with registration available through a provided link. Following the conference, the presentation will be made available on Quanterix's website. This event offers an opportunity for investors and interested parties to gain insights into Quanterix's operations and future prospects in the field of scientific discovery through biomarker detection.

Quanterix (NASDAQ: QTRX), a company specializing in ultrasensitive biomarker detection, has announced its plans to report second quarter 2024 financial results. The company will host a conference call on Thursday, August 8, 2024, at 4:30 p.m. E.T. to discuss these results. Prior to the call, Quanterix will issue a press release detailing the Q2 2024 earnings after the market closes on the same day.

Investors can access the live webcast from the News & Events page within the Investors section of the Quanterix website. For those interested in participating, pre-registration links are available for both webcast and audio-only options. An archived webcast replay will be accessible on the company's website for one year following the call.

Quanterix (NASDAQ: QTRX) presented new data at the Alzheimer's Association International Conference (AAIC) demonstrating a novel multi-marker approach for Alzheimer's disease (AD) detection. This approach significantly reduces the intermediate zone of a two-cutoff p-Tau 217 test while maintaining high accuracy above 90%. The multi-marker method combines p-Tau 217 with other AD-associated plasma biomarkers, including amyloid β 42, amyloid β 40, GFAP, and NfL, in an algorithm that provides a single risk score.

Key findings include:

• Reduced intermediate zone from 31.2% to 10.5% compared to p-Tau 217 alone
• Accurate amyloid classifications for 151 of 228 previously uncertain results
• Potential to provide diagnostic certainty for more patients

Quanterix plans to launch a multi-marker laboratory developed test later this year through its LucentAD product line.

Quanterix (NASDAQ: QTRX) has announced that its CEO, Masoud Toloue, and CFO, Vandana Sriram, will participate in the Scotiabank Healthcare 1x1 Day on June 20, 2024. Known for its ultrasensitive biomarker detection technology, Quanterix aims to showcase its advancements and strategies. For more details, visit their official website and explore their Simoa® technology.

Quanterix (NASDAQ: QTRX) announced the participation of its CEO Masoud Toloue and CFO Vandana Sriram at the 45th Annual Goldman Sachs Global Healthcare Conference. The company specializes in ultrasensitive biomarker detection to advance scientific discovery. The fireside chat presentation is scheduled for June 12, 2024, at 2:40 p.m. EST and will be webcast live. Replays will be available for a time post-conference. For more details, visit the Investor Relations section on Quanterix's website.